Literature DB >> 16371785

Intraocular concentrations of gatifloxacin and moxifloxacin in the anterior chamber via diffusion through the cornea using collagen shields.

Guy Kleinmann1, Scott Larson, Irmingard M Neuhann, Anne C Hunold, Russell LeBoyer, Scott Hickman, Nick Mamalis, Randall J Olson.   

Abstract

PURPOSE: To evaluate the penetration of gatifloxacin and moxifloxacin into the anterior chamber, and any adverse reaction to the cornea, using collagen shields presoaked in oversaturated solutions of the antibiotics.
METHODS: Collagen shields, presoaked for 10 minutes in an oversaturated solution of gatifloxacin or moxifloxacin, were placed on the surface of each of the corneas of 15 rabbits for a total of 30 eyes (15 in each group). The antibiotics were prepared by dissolving the powder form of the antibiotics in a solution until no further particulate could be further dissolved. Aqueous humor samples were taken 3.5 and 6 hours later.
RESULTS: The initial concentrations of gatifloxacin and moxifloxacin were 5.43 +/- 0.16 mg/mL and 3.14 +/- 0.22 mg/mL, respectively. The average concentration of gatifloxacin in the anterior chamber was higher than that of moxifloxacin at the 3.5-hour sample (6.32 +/- 2.67 microg/mL versus 3.55 +/- 3.5 microg/mL, P = 0.0034). The concentrations of both antibiotics, although decreased, remained relatively high at the 6-hour sample (1.39 +/- 1.13 microg/mL versus 0.816 +/- 0.6 microg/mL at 6 hours, respectively, P = 0.22). No obvious clinical or histologic signs of toxicity were noticed in either group.
CONCLUSION: Gatifloxacin and moxifloxacin showed good penetration into the anterior chamber with no obvious adverse reaction to the cornea. The concentrations in the anterior chamber exceeded the minimal inhibitory concentration (MIC) 90 of most organisms responsible for postoperative endophthalmitis (POE).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16371785     DOI: 10.1097/01.ico.0000170689.75207.5e

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  5 in total

1.  Release of Moxifloxacin From Corneal Collagen Shields.

Authors:  Siwei Zhou; Kristin M Hunt; Arman S Grewal; Kimberly M Brothers; Deepinder K Dhaliwal; Robert M Q Shanks
Journal:  Eye Contact Lens       Date:  2018-11       Impact factor: 2.018

2.  Diffusion of protein through the human cornea.

Authors:  Resmi A Charalel; Kristin Engberg; Jaan Noolandi; Jennifer R Cochran; Curtis Frank; Christopher N Ta
Journal:  Ophthalmic Res       Date:  2012-03-02       Impact factor: 2.892

3.  Comparing Combination Drop Therapy to a Standard Drop Regimen After Routine Cataract Surgery.

Authors:  Kerry D Solomon; Helga P Sandoval; Richard Potvin
Journal:  Clin Ophthalmol       Date:  2020-07-10

4.  Biocompatibility and drug release behavior of chitosan/poly (vinyl alcohol) corneal shield in vivo.

Authors:  Guo-Xing Li; Xin Gu; Hui-Yang Song; Kai-Hui Nan; Hao Chen
Journal:  Int J Clin Exp Med       Date:  2015-08-15

5.  Review of moxifloxacin hydrochloride ophthalmic solution in the treatment of bacterial eye infections.

Authors:  Darlene Miller
Journal:  Clin Ophthalmol       Date:  2008-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.